Skip to content
Clinical Trials – home
SwedenBack to Sweden

Clinical trials in Kungalv – page 9

476 clinical trials in Kungalv, Sweden. Every trial is listed in the EU Clinical Trials Register and updated daily.

SwedenOur site in SwedenKliniska-Provningar.se(opens in a new tab)
Kungalv at a glance
476
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

476 trials in Kungalv

Open in trial search

Study Comparing BMS-986393 CAR T Cell Therapy to Standard Treatments for Adults with Relapsed or Refractory Multiple Myeloma Resistant to Lenalidomide

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Carfilzomib
  • Sponsor:Celgene Corp.

Cardiac arrest

Recruiting

Study on the Effect of Adrenaline, Vasopressin, and Steroids on Survival in Cardiac Arrest Patients

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Argipressin
  • Sponsor:Tiohundra AB

Anaemia+1

Recruiting

Study of Elritercept for Treating Anemia in Adults with Low to Intermediate Risk Myelodysplastic Syndromes

Investigational
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Elritercept
  • Sponsor:Takeda Development Center Americas Inc.

Study on the Safety and Effectiveness of CRN04894 for Patients with Congenital Adrenal Hyperplasia

InvestigationalNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Atumelnant
  • Sponsor:Crinetics Pharmaceuticals Inc.

Study on Venetoclax, Obinutuzumab, and Pirtobrutinib for Patients with Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Obinutuzumab
  • Sponsor:University Of Cologne

Study on Revumenib, Azacitidine, and Venetoclax for Adults with Newly Diagnosed Acute Myeloid Leukemia Not Eligible for Intensive Chemotherapy

Registered drug
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Study Comparing Chemotherapy Options for Patients with Stage I Testicular Cancer: Bleomycin, Etoposide, Cisplatin vs. Carboplatin

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years
  • Substances:Bleomycin
  • Sponsor:St. Olavs Hospital HF

Study on Rituximab, Lenalidomide, and Tafasitamab for Treating High-Risk and Low-Risk Follicular Lymphoma Patients

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Lenalidomide
  • Sponsor:Karolinska University Hospital

Study on the Effectiveness and Safety of AZD0486 for Adults with Relapsed or Refractory Non-Hodgkin Lymphoma

InvestigationalNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Human Igg4 Kappa Monoclonal Antibody Against Cd3 And Cd19
  • Sponsor:AstraZeneca AB

Study on EGFR-Mutated Lung Cancer: Evaluating Dacomitinib, Afatinib, and Osimertinib for Patients Not Suitable for Curative Treatment

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Afatinib
  • Sponsor:Region Skane

Study on Mitomycin and BCG for Patients with Recurrent Non-Muscle Invasive Bladder Cancer

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Mitomycin
  • Sponsor:Aarhus University

Study on HPV Vaccine Timing for Patients After Stem Cell Transplantation Using Gardasil 9

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years
  • Substances:Human papillomavirus type 11 L1 protein
  • Sponsor:Vastra Gotalandsregionen

Other cities in Sweden

The busiest research cities in the country

All 66 cities in Sweden
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.